You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • LB0003 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: results from oral strategy, a phase 3b/4 randomised trial

Citation Tools

Article menu

Download PDFPDF

Oral Presentations
From classics to new: synthetic DMARDs in RA
LB0003 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: results from oral strategy, a phase 3b/4 randomised trial
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Fleischmann R, Mysler E, Hall S, et al
LB0003 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: results from oral strategy, a phase 3b/4 randomised trial
Annals of the Rheumatic Diseases 2017;76:149-150.